stella
beta
Osimertinib Combined With Savolitinib in the Treatment of NSCLC With Low Copy Number MET Amplification — Stella
Recruiting
Back to EGFR Positive Non-small Cell Lung Cancer trials
Phase 2 — Testing in a larger group (up to a few hundred people) to further evaluate safety and begin to assess effectiveness.
Trial locations
(1 site)
China
Qingdao Central Hospital, Qingdao
View full record on ClinicalTrials.gov